Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Therapeutics Remodulin Efficacy Shown By Secondary Data - Cmte.

Executive Summary

United Therapeutics' Remodulin efficacy may be based on secondary measures rather than primary endpoints because the pulmonary arterial hypertension therapy will be prescribed for a small population, FDA's Cardiovascular & Renal Drugs Advisory Committee agreed at its Aug. 9 meeting.
Advertisement

Related Content

United Therapeutics Filling $9 Mil. Of Remodulin Orders Following Approval
United Therapeutics Filling $9 Mil. Of Remodulin Orders Following Approval
United Therapeutics Remodulin “approvable”
United Therapeutics Remodulin “approvable”
Remodulin Phase IV Trials On Dosing, Duration Of Effect, Suggested by Cmte
Actelion Tracleer Registry Would Issue Liver Monitoring Reminders
Actelion Tracleer Registry Would Issue Liver Monitoring Reminders
Remodulin Phase IV Trials On Dosing, Duration Of Effect, Suggested by Cmte
Remodulin Phase IV Trials On Dosing, Duration Of Effect, Suggested by Cmte
Advertisement
UsernamePublicRestriction

Register

PS038356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel